AU2022387615A1 - Direct replacement genome editing - Google Patents

Direct replacement genome editing Download PDF

Info

Publication number
AU2022387615A1
AU2022387615A1 AU2022387615A AU2022387615A AU2022387615A1 AU 2022387615 A1 AU2022387615 A1 AU 2022387615A1 AU 2022387615 A AU2022387615 A AU 2022387615A AU 2022387615 A AU2022387615 A AU 2022387615A AU 2022387615 A1 AU2022387615 A1 AU 2022387615A1
Authority
AU
Australia
Prior art keywords
nucleic acid
endonuclease
aspects
dna
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022387615A
Other languages
English (en)
Inventor
Leonard CHAVEZ
Michael Chickering
Parbir GREWAL
Schaked Omer HALPERIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transit Therapeutics Inc
Original Assignee
Transit Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transit Therapeutics Inc filed Critical Transit Therapeutics Inc
Publication of AU2022387615A1 publication Critical patent/AU2022387615A1/en
Assigned to TRANSIT THERAPEUTICS, INC. reassignment TRANSIT THERAPEUTICS, INC. Request for Assignment Assignors: REPLACE THERAPEUTICS, LLC.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2022387615A 2021-11-12 2022-11-09 Direct replacement genome editing Pending AU2022387615A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163278886P 2021-11-12 2021-11-12
US63/278,886 2021-11-12
US202263341200P 2022-05-12 2022-05-12
US63/341,200 2022-05-12
PCT/US2022/079567 WO2023086834A1 (en) 2021-11-12 2022-11-09 Direct replacement genome editing

Publications (1)

Publication Number Publication Date
AU2022387615A1 true AU2022387615A1 (en) 2024-05-23

Family

ID=86324212

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022387615A Pending AU2022387615A1 (en) 2021-11-12 2022-11-09 Direct replacement genome editing

Country Status (8)

Country Link
US (2) US20230151353A1 (https=)
EP (1) EP4430207A4 (https=)
JP (1) JP2024543481A (https=)
AU (1) AU2022387615A1 (https=)
CA (1) CA3237317A1 (https=)
IL (1) IL312727A (https=)
MX (1) MX2024005787A (https=)
WO (1) WO2023086834A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024233949A1 (en) * 2023-05-11 2024-11-14 Replace Therapeutics, Llc Revision of genetic material using direct replacement editing
AU2024344127A1 (en) * 2023-09-22 2026-04-02 Revision Bio Corporation Dna ligase compositions, methods, and uses thereof
AU2024347035A1 (en) * 2023-09-22 2026-04-02 Revision Bio Corporation Dna-dependent dna polymerase compositions, methods, and uses thereof
WO2025226730A1 (en) * 2024-04-22 2025-10-30 Transit Therapeutics, Inc. Revision of genetic material using direct replacement editing
WO2025235828A2 (en) * 2024-05-08 2025-11-13 The General Hospital Corporation Engineered prime editors for treating genetic deafness

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10221442B2 (en) * 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US20190330659A1 (en) * 2016-07-15 2019-10-31 Zymergen Inc. Scarless dna assembly and genome editing using crispr/cpf1 and dna ligase
US11649442B2 (en) * 2017-09-08 2023-05-16 The Regents Of The University Of California RNA-guided endonuclease fusion polypeptides and methods of use thereof
CA3138576A1 (en) * 2019-05-16 2020-11-19 Trustees Of Boston University Regulated synthetic gene expression systems
US20230008217A1 (en) * 2019-12-17 2023-01-12 Agilent Technologies, Inc. Ligation-based gene editing using crispr nickase
US20230037794A1 (en) * 2019-12-23 2023-02-09 The Broad Institute, Inc. Programmable dna nuclease-associated ligase and methods of use thereof
AU2021236683A1 (en) * 2020-03-19 2022-11-17 Intellia Therapeutics, Inc. Methods and compositions for directed genome editing

Also Published As

Publication number Publication date
CA3237317A1 (en) 2023-05-19
US20230151353A1 (en) 2023-05-18
WO2023086834A1 (en) 2023-05-19
EP4430207A1 (en) 2024-09-18
MX2024005787A (es) 2024-07-30
EP4430207A4 (en) 2026-03-11
IL312727A (en) 2024-07-01
US20250179468A1 (en) 2025-06-05
JP2024543481A (ja) 2024-11-21

Similar Documents

Publication Publication Date Title
US20250179468A1 (en) Direct replacement genome editing
CA3236512C (en) Compositions and methods for treating hemoglobinopathies
KR102877920B1 (ko) 티틴-기반 근증 및 다른 티틴성병증의 치료를 위한 물질 및 방법
CN114207130A (zh) 用于从白蛋白基因座进行转基因表达的组合物和方法
US11530421B2 (en) Self-inactivating endonuclease-encoding nucleic acids and methods of using the same
JP2022534809A (ja) 操作されたｃａｓｘシステム
WO2020082041A1 (en) Nucleic acid constructs and methods of use
KR20220123398A (ko) 합성 가이드 rna, 이의 조성물, 방법 및 용도
KR20010071227A (ko) 무세포 키메라플라스티 및 이형이중나선 돌연변이성벡터를 진핵세포에 이용
EP4709870A1 (en) Revision of genetic material using direct replacement editing
CN116801913A (zh) 用于靶向bcl11a的组合物和方法
US20230337645A1 (en) Nuclease-mediated repeat expansion
JP2023527464A (ja) ＳＡＲＭ１の両対立ｋ遺伝子ノックアウト
JP2023549139A (ja) 新規ｏｍｎｉ－５０ ｃｒｉｓｐｒヌクレアーゼ－ｒｎａ複合体
CN117729926A (zh) 用于使碱基编辑器自失活的组合物和方法
US20240173432A1 (en) Compositions and Methods for Treatment of Myotonic Dystrophy Type 1 with CRISPR/SluCas9
CN120677236A (zh) 工程化omni-50核酸酶变体
CN118541494A (zh) 直接替换基因组编辑
US20220056438A1 (en) Gene-editing compositions and methods to modulate faah for treatment of neurological disorders
KR20230016751A (ko) 염기 편집기 및 이의 용도
US20240425850A1 (en) Noncanonical crRNA for Highly Efficient Genome Editing
US20250288690A1 (en) Rna base editing compositions, systems, methods and uses thereof
WO2025226730A1 (en) Revision of genetic material using direct replacement editing
WO2023220654A2 (en) Effector protein compositions and methods of use thereof
HK40061317A (en) Compositions and methods for transgene expression from an albumin locus

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TRANSIT THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): REPLACE THERAPEUTICS, LLC.